A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab Among Chinese Healthy Subjects
ObjectiveThis study was conducted to explore the tolerance, variability, pharmacokinetics (PK), and pharmacodynamics (PD) of denosumab biosimilar (QL1206) in healthy Chinese subjects.MethodsThis is a randomized, double-blind, two-arm, parallel study performed to examine the bioequivalence of denosum...
Saved in:
Main Authors: | Hong Zhang (Author), Min Wu (Author), Xiaoxue Zhu (Author), Cuiyun Li (Author), Xiaojiao Li (Author), Jixuan Sun (Author), Chengjiao Liu (Author), Quan Liu (Author), Wei Wei (Author), Junqi Niu (Author), Yanhua Ding (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2020-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double‐blind, parallel‐controlled, phase 1 study
by: Hong Zhang, et al.
Published: (2021) -
A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of HOT-3010 to Adalimumab Among Healthy Chinese Male Subjects
by: Hong Zhang, et al.
Published: (2021) -
MB09, a denosumab biosimilar candidate: Biosimilarity demonstration in a phase I study in healthy subjects
by: Monika Tomaszewska‐Kiecana, et al.
Published: (2024) -
A Biosimilarity Study Between QX001S and Ustekinumab in Healthy Chinese Male Subjects
by: Lei Gao, et al.
Published: (2021) -
Association of Variability and Pharmacogenomics With Bioequivalence of Gefitinib in Healthy Male Subjects
by: Hong Zhang, et al.
Published: (2018)